Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.


We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by Reaxense.


In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.


Our high-tech, dedicated method is applied to construct targeted libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.


PARTNER
Receptor.AI
 
UPACC
Q9H7C9

UPID:
AAMDC_HUMAN

ALTERNATIVE NAMES:
Adipogenesis associated Mth938 domain-containing protein

ALTERNATIVE UPACC:
Q9H7C9; Q96AQ4; Q9Y6B1

BACKGROUND:
Mth938 domain-containing protein plays a crucial role in the differentiation of preadipocytes into adipocytes, a fundamental process in adipose tissue development. This protein's function underscores its significance in the regulation of adipogenesis, the formation of fat cells from precursor cells.

THERAPEUTIC SIGNIFICANCE:
Exploring the functions of Mth938 domain-containing protein offers a pathway to novel therapeutic approaches. Given its critical role in adipocyte formation, targeting this protein could lead to breakthroughs in treating metabolic disorders, including obesity and diabetes, by modulating fat tissue development.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.